Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Unity Biotechnology ( (UNBX) ) has shared an announcement.
On September 18, 2025, Unity Biotechnology held a special meeting of stockholders where the approval of the company’s liquidation and dissolution was voted on. The stockholders approved both the Dissolution Proposal and the Adjournment Proposal, granting the Board of Directors the authority to proceed with the dissolution at their discretion.
The most recent analyst rating on (UNBX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Unity Biotechnology stock, see the UNBX Stock Forecast page.
Spark’s Take on UNBX Stock
According to Spark, TipRanks’ AI Analyst, UNBX is a Underperform.
Unity Biotechnology’s overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.
To see Spark’s full report on UNBX stock, click here.
More about Unity Biotechnology
Unity Biotechnology, Inc. operates in the biotechnology industry, focusing on the development of therapeutics to slow, halt, or reverse diseases of aging.
Average Trading Volume: 581,294
Technical Sentiment Signal: Sell
Current Market Cap: $998.3K
See more data about UNBX stock on TipRanks’ Stock Analysis page.